Prognostic value of cystatin C in relation to other markers of renal function in early prediction of hospital mortality and major cardiac adverse events in patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F18%3A73591735" target="_blank" >RIV/61989592:15110/18:73591735 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00104277

Výsledek na webu

<a href="https://e-coretvasa.cz/pdfs/cor/2018/04/09.pdf" target="_blank" >https://e-coretvasa.cz/pdfs/cor/2018/04/09.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2017.11.005" target="_blank" >10.1016/j.crvasa.2017.11.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prognostic value of cystatin C in relation to other markers of renal function in early prediction of hospital mortality and major cardiac adverse events in patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention

Popis výsledku v původním jazyce

Introduction: Cystatin C has been implicated as a prognostic marker in cardiovascular diseases. The aim of prospective study was to evaluate the benefits of measuring cystatin C for prognostic stratification to predict hospital mortality and the rates of major cardiac adverse events (MACE) in ST elevation myocardial infarction (STEMI) patients and to compare cystatin C to other markers of renal function and Global Registry of Acute Coronary Events (GRACE) score. Methods: A total of 659 consecutive patients (479 men, mean age 65 years) from a prospective study on acute STEMI treated by primary percutaneous coronary intervention (PCI) were evaluated. Standard laboratory tests including cystatin C, troponin T, NT-terminal fragment of brain natriuretic peptide (NT-proBNP), markers of renal function were assessed on admission in all patients. Using c-statistic, the ability of cystatin C, other biomarkers and GRACE score to predict hospital mortality and MACE (acute coronary syndrome recurrence, stroke event, definite in-stent thrombosis and mortality) rate was evaluated. Results: All-cause hospital mortality and MACE occurrence were 4% (n = 26) resp. 6.8% (n = 45). Cystatin C, creatinine, urea, glomerular filtration rate, troponin T, NT-proBNP and GRACE on admission were identified as significant prognostic risk markers. Serum cystatin C level and GRACE score were significantly higher in non-survivors (1.65 +/- 0.91 vs. 0.97 +/- 0.41 mg/mL; P &lt; 0.001 resp. 138 +/- 43 vs. 99 +/- 31; P &lt; 0.001). The area under the curve (AUC) values for mortality and MACE rate prediction for cystatin C and GRACE score were 0.83 and 0.88, respectively 0.66 and 0.72 (all P &lt; 0.001) with optimal cut-off values of 1.3 mg/mL for cystatin C and 136 for GRACE score. Cystatin C above cut-off &gt; 1.30 mg/L was associated with the highest adjusted odds ratio (OR) 3.85 (95% confidence interval 2.36-6.38; P &lt; 0.001), and predicted in-hospital mortality with 77% sensitivity and 86% specificity. The addition of cystatin C to the GRACE score (OR 1.05, 95% confidence interval 1.04-1.07; P &lt; 0.001) was not significantly associated with improved risk stratification. Conclusions: Cystatin C is a predictor of early outcome comparable with the GRACE score in patients with STEMI. (c) 2017 The Czech Society of Cardiology. Published by Elsevier Sp. zo.o. All rights reserved.

Název v anglickém jazyce

Prognostic value of cystatin C in relation to other markers of renal function in early prediction of hospital mortality and major cardiac adverse events in patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention

Popis výsledku anglicky

Introduction: Cystatin C has been implicated as a prognostic marker in cardiovascular diseases. The aim of prospective study was to evaluate the benefits of measuring cystatin C for prognostic stratification to predict hospital mortality and the rates of major cardiac adverse events (MACE) in ST elevation myocardial infarction (STEMI) patients and to compare cystatin C to other markers of renal function and Global Registry of Acute Coronary Events (GRACE) score. Methods: A total of 659 consecutive patients (479 men, mean age 65 years) from a prospective study on acute STEMI treated by primary percutaneous coronary intervention (PCI) were evaluated. Standard laboratory tests including cystatin C, troponin T, NT-terminal fragment of brain natriuretic peptide (NT-proBNP), markers of renal function were assessed on admission in all patients. Using c-statistic, the ability of cystatin C, other biomarkers and GRACE score to predict hospital mortality and MACE (acute coronary syndrome recurrence, stroke event, definite in-stent thrombosis and mortality) rate was evaluated. Results: All-cause hospital mortality and MACE occurrence were 4% (n = 26) resp. 6.8% (n = 45). Cystatin C, creatinine, urea, glomerular filtration rate, troponin T, NT-proBNP and GRACE on admission were identified as significant prognostic risk markers. Serum cystatin C level and GRACE score were significantly higher in non-survivors (1.65 +/- 0.91 vs. 0.97 +/- 0.41 mg/mL; P &lt; 0.001 resp. 138 +/- 43 vs. 99 +/- 31; P &lt; 0.001). The area under the curve (AUC) values for mortality and MACE rate prediction for cystatin C and GRACE score were 0.83 and 0.88, respectively 0.66 and 0.72 (all P &lt; 0.001) with optimal cut-off values of 1.3 mg/mL for cystatin C and 136 for GRACE score. Cystatin C above cut-off &gt; 1.30 mg/L was associated with the highest adjusted odds ratio (OR) 3.85 (95% confidence interval 2.36-6.38; P &lt; 0.001), and predicted in-hospital mortality with 77% sensitivity and 86% specificity. The addition of cystatin C to the GRACE score (OR 1.05, 95% confidence interval 1.04-1.07; P &lt; 0.001) was not significantly associated with improved risk stratification. Conclusions: Cystatin C is a predictor of early outcome comparable with the GRACE score in patients with STEMI. (c) 2017 The Czech Society of Cardiology. Published by Elsevier Sp. zo.o. All rights reserved.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

COR ET VASA

ISSN

0010-8650

e-ISSN

—

Svazek periodika

60

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

9

Strana od-do

"E352"-"E360"

Kód UT WoS článku

000442902500003

EID výsledku v databázi Scopus

2-s2.0-85036630064